© IFPMA
The Threat of False Friends - Fake Medicines
11 December 2012, Geneva
The falsification of medicines is first and foremost a crime against patient and public health . This growing issue requires a concerted multi-stakeholder effort, including the World Health Organization, governments, healthcare providers, patients, and the private sector. Addressing this problem successfully requires collaborative action and the creation of a global policy environment that recognizes, prioritizes, and effectively addresses the major aspects of the falsification of medicines.
The IFPMA invites you to the next session of the Geneva Pharma Forum for a panel discussion on how counterfeit medicines are being addressed. This session will also feature the launch of a study by the School of Pharmacy at the University College of London in conjunction with Matrix Insights as well as a new International Pharmaceutical Federation (FIP) - IFPMA advocacy tool. They both offer suggestions for coordinated actions against counterfeit medicines to foster the general public and governments’ action.
Participants will include representative of national missions from UN member state missions in Geneva, key decision-makers from health-related intergovernmental and nongovernmental organizations plus senior pharmaceutical industry executives.
15 May 2013,
Scientific and regulatory experts meet in Moscow to explore harmonized approaches for...
18 April 2013,
Vaccine experts recommend practical actions to support vaccine innovation and access around the...
20 May 2013, Geneva, Switzerland
The Annual IFPMA Reception on the occasion of the 66th World Health Assembly

UPDATED! Developing World Health Partnerships Directory
The research-based pharmaceutical industry engages in a wide range of public-private partnerships...

IFPMA Code of Practice
Expanded IFPMA Code of Practice updates ethical and professional standards for interacting with...

IFPMA Clinical Trials Portal and Joint Positions on Clinical Trial Results Publication and...
Important online sources of clinical trials information


